durlobactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 5731 | 1467829-71-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor, that protects sulbactam from degradation by certain serine-beta-lactamases. Durlobactam alone does not have antibacterial activity against Acinetobacter baumannii-calcoaceticus complex (ABC) isolates but in combination with sulbactam it has been approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 23, 2023 | FDA | ENTASIS THERAP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA MoA | N0000000202 | beta Lactamase Inhibitors |
| FDA EPC | N0000175930 | beta Lactamase Inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 429271009 | |
| Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex | indication | 445780006 | |
| Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex | indication | 1010634002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9623014 | April 2, 2033 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 10376499 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | 9968593 | Nov. 17, 2035 | TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2028 | NEW CHEMICAL ENTITY |
| EQ 500MG BASE/VIAL; EQ 500MG BASE/VIAL;EQ 1GM BASE/VIAL | XACDURO (COPACKAGED) | ENTASIS THERAP | N216974 | May 23, 2023 | RX | POWDER | INTRAVENOUS | May 23, 2033 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Betalactamase OXA24 | Enzyme | INHIBITOR | IC50 | 6.72 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Beta-lactamase | Enzyme | INHIBITOR | IC50 | 7.86 | SCIENTIFIC LITERATURE | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEMBL4298137 | ChEMBL_ID |
| C000626193 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12693 | IUPHAR_LIGAND_ID |
| DB16704 | DRUGBANK_ID |
| 019452 | NDDF |
| 019453 | NDDF |
| C5420986 | UMLSCUI |
| CHEMBL4297378 | ChEMBL_ID |
| 10824 | INN_ID |
| 1467157-21-6 | SECONDARY_CAS_RN |
| 89851852 | PUBCHEM_CID |
| 2639089 | RXNORM |
| D11591 | KEGG_DRUG |
| PSA33KO9WA | UNII |
| 41619 | MMSL |
| d10064 | MMSL |
Pharmaceutical products:
None